Structolite Plaster

Product Description

Structolite Plaster was a lightweight, gypsum-based base coat plaster manufactured by United States Gypsum (USG), one of the dominant suppliers of interior finishing materials throughout the twentieth century. Produced from approximately 1955 through 1972, Structolite was designed as a versatile substrate plaster suitable for application over a wide range of masonry and lath surfaces. Its relatively low density compared to conventional sand-aggregate plasters made it a practical choice for commercial construction, institutional buildings, and industrial facilities where speed of application and material handling were important operational considerations.

The product was marketed under the broader USG product line and found widespread use in hospitals, schools, government facilities, and industrial plants constructed or renovated during its production window. Structolite was applied by professional plasterers as a scratch and brown coat, forming the foundational layer beneath finish coat plasters. Its perlite aggregate formulation gave it good workability and reduced the overall weight load on building assemblies, contributing to its commercial popularity during the postwar construction boom.

Because Structolite was manufactured during a period when asbestos was routinely incorporated into gypsum and plaster products to improve fire resistance, tensile strength, and workability, the product falls under scrutiny for asbestos content during the years it was produced. United States Gypsum has been the subject of extensive asbestos-related litigation arising from its broad portfolio of construction products, of which Structolite is one documented example.

Asbestos Content

Structolite Plaster is documented as having contained chrysotile asbestos during its production years of 1955 through 1972. Chrysotile, also known as white asbestos, is the most commercially prevalent form of asbestos and belongs to the serpentine mineral group. Although chrysotile fibers have a curled morphology that differs structurally from the straight amphibole fibers found in products like amosite or crocidolite, chrysotile has been classified as a known human carcinogen by the International Agency for Research on Cancer (IARC) and the U.S. National Toxicology Program. Regulatory bodies including OSHA and the EPA recognize no safe level of exposure to any form of asbestos fiber.

In plaster products, chrysotile asbestos served multiple functional purposes. Its fibrous structure reinforced the plaster matrix, helping to resist cracking during the drying and curing process. Asbestos also contributed thermal resistance properties and improved the overall binding characteristics of the mix. These performance benefits were well understood within the building materials industry during the mid-twentieth century, even as evidence linking asbestos fiber inhalation to serious disease was accumulating in scientific and medical literature.

The use of chrysotile in Structolite reflects a broader manufacturing pattern across USG’s product line during this era. Product testing, industrial hygiene records, and litigation discovery materials have collectively established that chrysotile-containing plaster products were produced and distributed widely before regulatory restrictions began to take effect in the early 1970s.

How Workers Were Exposed

Workers most directly affected by Structolite Plaster were those involved in the industrial and commercial construction trades, including plasterers, lathers, construction laborers, and maintenance workers employed at facilities where the product was applied or disturbed during later renovation or demolition activities.

Asbestos fiber release from plaster products occurs in two primary contexts: during initial application and mixing, and during subsequent disturbance of hardened material. When Structolite was mixed on a job site — a process that involved opening bags of dry plaster compound, adding water, and mechanically or manually blending the material — fine airborne dust containing chrysotile fibers was generated. Workers operating in enclosed or poorly ventilated spaces faced the greatest inhalation risk during this phase.

Once applied and cured, Structolite presented ongoing exposure risks during cutting, chipping, sanding, grinding, or demolition activities. Industrial maintenance workers, renovation crews, and building tradespeople performing later-stage modifications to structures containing Structolite plaster could disturb the hardened material and release respirable fibers into the surrounding air. OSHA standards established under 29 CFR 1910.1001 and 29 CFR 1926.1101 now govern occupational asbestos exposure, but many of the workers harmed by Structolite performed their work prior to the implementation of these protective regulations.

Secondary exposure — sometimes called para-occupational exposure — has also been documented in litigation contexts, involving household members of workers who inadvertently carried asbestos fibers home on clothing, skin, and hair.

The latency period for asbestos-related diseases typically ranges from ten to fifty years following initial exposure, which means workers exposed to Structolite during its production and peak use years from 1955 through the early 1970s may be receiving diagnoses today. Documented asbestos-related conditions associated with occupational plaster work include mesothelioma, asbestosis, lung cancer, and pleural disease.

Documented Trust Fund / Legal Options

Structolite Plaster is a Tier 2 litigation product. There is no dedicated asbestos bankruptcy trust fund established for claims specifically related to this product. Individuals seeking legal recourse for injuries linked to Structolite Plaster must pursue compensation through civil litigation rather than through trust fund claim submission.

Litigation records document claims filed against United States Gypsum in connection with its asbestos-containing construction products, including plasters and related materials manufactured during the mid-twentieth century. Plaintiffs alleged that USG knew or had reason to know of the hazards associated with asbestos-containing products it manufactured and distributed, and that the company failed to provide adequate warnings to workers, contractors, and end users who would foreseeably come into contact with those products.

Plaintiffs in these actions have alleged development of serious asbestos-related conditions — including mesothelioma, lung cancer, and asbestosis — following occupational exposure to Structolite and other USG plaster products. Litigation records document claims arising from exposure in industrial, commercial, and institutional settings consistent with the documented use profile of Structolite Plaster.

Individuals who believe they were exposed to Structolite Plaster and have since been diagnosed with an asbestos-related disease should consult an attorney experienced in asbestos litigation. A qualified attorney can evaluate the strength of a claim based on documented exposure history, employment records, medical diagnosis, and the applicable statute of limitations in the relevant jurisdiction. Statutes of limitations for asbestos personal injury claims typically begin running from the date of diagnosis rather than the date of exposure, a legal principle known as the discovery rule.

Given the involvement of large commercial entities such as United States Gypsum in extensive asbestos litigation, legal counsel familiar with the history of USG product liability cases may be particularly well-positioned to assess available legal options.

If you or a family member has been diagnosed with mesothelioma, asbestosis, or another asbestos-related illness and has a history of working with or around Structolite Plaster, contact an asbestos litigation attorney promptly to preserve your legal rights.